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OBJECTIVES: To analyze quantitative changes in glaucoma
treatment strategies between 1997 and 2003 in France.
METHODS: The number of trabeculectomies and other glau-
coma surgeries was extracted from the national database of the
French Diagnosis Related Group system, which includes data for
both public and private hospitals. Numbers of patients treated
per year were estimated from drug unit sales using deﬁned daily
doses for each drug. RESULTS: New medical treatments of glau-
coma and ocular hypertension, introduced in France between
1997 and 2003, allowed to treat 557,000 patients. In 2003, 63%
of patients treated with these new medicines were receiving
prostaglandins (39% latanoprost, 9% travoprost, 8% the ﬁxed
combination of latanoprost + timolol, and 7% bimatoprost), 13%
brinzolamide, 13% the ﬁxed combination of dorzolamide +
timolol and 11% brimonidine. During the same period, tra-
beculectomies declined by 38% (−48% in public hospitals and 
−32% in private clinics), while the total number of glaucoma surg-
eries declined by 22% (−34% in public hospitals and −14% in
private clinics). Hospital days related to open-angle glaucoma
surgery declined by 51%. There is a strong correlation (r = −0.97)
between the reduction of glaucoma surgery and the increase in
the number of patients treated with prostaglandins during the
study period. CONCLUSIONS: Between 1997 and 2003, new
glaucoma drugs, primarily prostaglandins, by improving IOP
control and stabilizing disease progression in many patients, may
have delay surgery, reducing glaucoma surgery by 22%.
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OBJECTIVES: Glaucoma is an optic neuropathy associated with
visual ﬁeld loss. Uncontrolled disease may progress to total
blindness. Currently, the only treatment for glaucoma is to lower
intraocular pressure. First-line treatment involves using β-
blockers or prostaglandin analogs. β-blockers and other intraoc-
ular pressure lowering agents may be used as adjunctive therapy
to prostaglandins. We quantiﬁed the use of adjunctive therapy
in association with prostaglandins. METHODS: We conducted
a cohort study using claims data from Québec, Canada. We iden-
tiﬁed all patients with a ﬁrst claim for bimatoprost, latanoprost
or travoprost between May 24, 2003 and February 28, 2005,
and analyzed adjunctive therapy utilization in the ﬁrst 12 months
of prostaglandin use. Use of adjunctive therapy was identiﬁed 
by at least two intermittent claims other than the index
prostaglandin in the 12-month follow-up period from their ﬁrst
prostaglandin prescription. Statistical and descriptive analyses
were performed using SAS 9.1. RESULTS: In total, 7982 patients
were included. The average age was 74 (±10) years, 60% were
females. Prostaglandin users who were naïve to any glaucoma
treatment, i.e. who started their therapy with prostaglandins,
comprised 60%, 58%, and 57% of the bimatoprost, latanoprost
and travoprost cohorts, respectively (no signiﬁcant differences,
χ2 = 1.20, p = 0.550). The proportions of patients requiring
adjunctive therapy were 40%, 35%, and 33% for bimatoprost,
latanoprost and travoprost, respectively. A signiﬁcantly higher
proportion of adjunctive therapy was associated with bimato-
prost users (bimatoprost vs. latanoprost: χ2 = 11.33, p < 0.001;
bimatoprost vs. travoprost: χ2 = 10.94, p < 0.001). CONCLU-
SIONS: Between 33% and 40% of continuous prostaglandin
users required adjunctive therapy in the ﬁrst 12 months. The
travoprost cohort had the lowest percentage of patients who
required adjunctive therapy. Further research is warranted for
incident vs. prevalent analyses, as well as economic impact.
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OBJECTIVE: To develop an approach to measuring current use
of topical ocular hypotensive medication that accounts for both
persistence (continuous use) and discontinuation followed by
restarting therapy. METHODS: This retrospective cohort study
of pharmacy claims submitted to a large national U.S. adminis-
trative claims database, analyzed claims for 3 prostaglandin ana-
logues (bimatoprost, latanoprost, and travoprost [index
prostaglandin]) submitted between 2001 and 2002. Patients who
did not have coverage in the plan for the preceding 180 days or
had been prescribed any ocular prostaglandin in the prior 180
days were excluded. Persistence was deﬁned as neither discon-
tinuing nor changing the index prostaglandin. The number of
current users of the index prostaglandin at day 180 was the sum
of patients who persisted with the index prostaglandin plus
patients who restarted the index prostaglandin following a dis-
continuation. RESULTS: Of the 4356 patients who started
prostaglandin therapy, 2503 (57%) were potential current 
users (were still plan members and had not switched ocular
hypotensive therapies after 180 days). Just over half of these,
(1356/2503, 54%) were actual current users, including 879/2503
(35%) who persisted with their index prostaglandin and
477/2503 (19%) who restarted their index prostaglandin. More
than half of those who discontinued their index prostaglandin
failed to restart any topical therapy (827/1624, 51%) before the
end of the study or their plan enrollment. CONCLUSIONS: Pre-
vious studies showing poor persistence for ocular hypotensive
therapy have not accounted for restarts. Including patients who
discontinue and restart therapy reﬂects current use more accu-
rately, but persistence remains a challenge.
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